Shuhua Yi
Blood Disease Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, CAMS) · Hematology Hospital, Chinese Academy of Medical Sciences · Institute of Hematology & Blood Diseases Hospital, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shuhua Yi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07682415 · Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL:Stop Trial 2.0Yi Shuhua · not yet recruiting · CLL / SLL · principal investigator
- Ph2NCT07441993 · Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Marginal Zone Lymphoma · principal investigator
- Ph2NCT07299149 · Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular LymphomaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Follicular Lymphoma · principal investigator
- Ph2NCT07259122 · A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaInstitute of Hematology & Blood Diseases Hospital, China · not yet recruiting · Waldenström Macroglobulinemia (WM) · principal investigator
- Ph2NCT07165769 · Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical TrialInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli,SBLPN · principal investigator
- Ph2NCT06530576 · Thalidomide for the Symptomatic Large Granular Lymphocytic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · T-LGL Leukemia, NK-LGL Leukemia · principal investigator
- Ph2NCT06530550 · PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia · principal investigator
- Ph2NCT06504199 · Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT06415708 · Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China · unknown · B Cell Lymphoma · principal investigator
- Ph1/Ph2NCT05944978 · A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological MalignanciesSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Relapsed/Refractory Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT05914662 · Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMInstitute of Hematology & Blood Diseases Hospital, China · unknown · Waldenstrom Macroglobulinemia · principal investigator
- Ph2NCT05846750 · Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Marginal Zone Lymphoma · principal investigator
- N/ANCT05846763 · Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World StudyInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Follicular Lymphoma · principal investigator
- Ph2NCT05287984 · Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLInstitute of Hematology & Blood Diseases Hospital, China · unknown · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed · principal investigator
- Ph2NCT04463953 · Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's MacroglobulinemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Waldenström Macroglobulinemia · principal investigator
- Ph4NCT02858804 · EDOCH Alternating With DHAP for New Diagnosed Younger MCLInstitute of Hematology & Blood Diseases Hospital, China · completed · Mantle Cell Lymphoma · principal investigator
- Ph4NCT02844309 · The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WMInstitute of Hematology & Blood Diseases Hospital, China · completed · Waldenström Macroglobulinemia · principal investigator
- Ph4NCT02844361 · Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström MacroglobulinemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Waldenström Macroglobulinemia · principal investigator
- Ph4NCT02844322 · The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström MacroglobulinemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Waldenström Macroglobulinemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:48 UTC. The ranking covers the 200 most relevant of 161 PubMed records, and a shared surname and initials can bring in a namesake. All 161 on PubMed
- Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.Nat Mater · 2017703 citationsRCR 23.2
- 160 citationsRCR 6.1
- 94 citationsRCR 1.8
- Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.J Clin Invest · 202294 citationsRCR 5.8
- Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.Ann Oncol · 202492 citationsRCR 10.8
- The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.Clin Cancer Res · 201588 citationsRCR 2.5
- A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.Clin Cancer Res · 200585 citationsRCR 1.7
- 85 citationsRCR 5.6
- Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.JAMA Oncol · 202178 citationsRCR 4.6
- Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.Clin Cancer Res · 202075 citationsRCR 3.1